The Dutch biopharmaceutical company NewAmsterdam Pharma (NASDAQ: NAMS), focused on cardiovascular treatments, has seen its stock price soar by 232% since going public through a SPAC in 2022, with an increase of 36% this year. Although the company has not yet turned a profit, analysts believe the rise in its stock price is mainly attributed to the steady progress of its drug development pipeline. Currently, the company's stock price is $35.25, with a market value of $4 billion.